These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2943011)

  • 21. Endocrine therapy for advanced stage D prostate cancer.
    Taylor TK
    Urol Nurs; 1991 Sep; 11(3):22-6. PubMed ID: 1833823
    [No Abstract]   [Full Text] [Related]  

  • 22. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
    Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
    Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Lunglmayr G
    Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
    Ryan PG; Peeling WB
    Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Lunglmayr G
    Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
    [No Abstract]   [Full Text] [Related]  

  • 26. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment with the LH-RH agonist (Zoladex depot) in patients with puberty praecox].
    Bassi F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():33-7. PubMed ID: 2150502
    [No Abstract]   [Full Text] [Related]  

  • 28. [How can a nursing team participate in a clinical trial? Zoladex, flutamide trial].
    Guidez C
    Soins; 1990 Sep; (540):53. PubMed ID: 2151069
    [No Abstract]   [Full Text] [Related]  

  • 29. Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
    Carvalho AP; de Moura JL; Denis L; Newling D; Smith P; Bono A; Sylvester R; De Pauw M; Ongena P
    Prog Clin Biol Res; 1989; 303():129-43. PubMed ID: 2528736
    [No Abstract]   [Full Text] [Related]  

  • 30. Goserelin--depot preparation of LHRH analogue used in the treatment of endometriosis.
    Shaw RW
    Prog Clin Biol Res; 1990; 323():383-92. PubMed ID: 2137621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Isurugi K; Niijima T; Aso Y; Araki T
    Hinyokika Kiyo; 1988 Feb; 34(2):369-82. PubMed ID: 2967622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LHRH-analogues therapy for metastatic prostate cancer.
    Debruyne FM; Fernandez del Moral P; Geboers AD
    Prog Clin Biol Res; 1988; 260():27-39. PubMed ID: 2966406
    [No Abstract]   [Full Text] [Related]  

  • 33. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
    Murphy GP; Greco J; Huben R
    Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer.
    Tyrrell C
    Horm Res; 1989; 32 Suppl 1():218-20. PubMed ID: 2533154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoladex in the treatment of premenopausal metastatic breast cancer patients.
    Kaufmann M
    Horm Res; 1989; 32 Suppl 1():202-5. PubMed ID: 2533150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
    Waymont B; Lynch TH; Dunn JA; Emtage LA; Arkell DG; Wallace DM; Blackledge GR
    Br J Urol; 1992 Jun; 69(6):614-20. PubMed ID: 1386272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Goserelin (Zoladex) depot in the treatment of endometriosis. Zoladex Endometriosis Study Group.
    Reichel RP; Schweppe KW
    Fertil Steril; 1992 Jun; 57(6):1197-202. PubMed ID: 1534773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
    Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
    Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.